Baseline characteristics and treatment of patients in Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF)

• AIMS: To describe the baseline characteristics and treatment of the patients randomized in the Prospective comparison of ARNi with ACEi to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF), testing the hypothesis that the strategy of simultaneously blocking the renin-angiotensin-aldosterone system and augmenting natriuretic peptides with LCZ696 200 mg bid is superior to enalapril 10 mg bid in reducing mortality and morbidity in patients with heart failure and reduced ejection fraction (HF-REF). METHODS: Key demographic, clinical and laboratory findings, along with baseline treatment, are reported and compared with those of patients in the treatment arm of the Studies Of Left Ventricular Dysfunction (SOLVD-T) and more contemporary drug and device trials in HF-REF. RESULTS: The mean age of patients in PARADIGM-HF is 64 (SD 11) years and 78% are male, in keeping with both SOLVD-T and more recent trials. Despite extensive background therapy with beta-blockers (94% patients) and mineralocorticoid receptor antagonists (58%), patients in PARADIGM-HF have persisting symptoms and signs, reduced health related quality of life, a low LVEF (mean 29+/-SD 6%) and elevated N terminal-proB type-natriuretic peptide levels (median 1611 inter-quartile range 887-3205 pg/ml). CONCLUSION: PARADIGM-HF will determine whether LCZ696 is more beneficial than enalapril when added to other disease-modifying therapies and if further augmentation of endogenous natriuretic peptides will reduce morbidity and mortality in HF-REF.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine (hsv//eng)

Nyckelord

heart failure

treatment

prognosis

Publikations- och innehållstyp

ref (ämneskategori)

art (ämneskategori)